Skip to main content

Advertisement

Table 5 Contribution of LAP to the risk of CVD and all-cause mortality, independent of common CVD risk factors.

From: Predictive performances of lipid accumulation product vs. adiposity measures for cardiovascular diseases and all-cause mortality, 8.6-year follow-up: Tehran lipid and glucose study

   Men Women
   HR* (95% CIs) P-value HR* (95% CIs) P-value
CVD Global CVD risk <20% 1.07 (0.80-1.42) 0.643 1.46 (1.05-2.03) 0.025
  Global CVD risk ≥20% 1.09 (0.90-1.32) 0.374 1.20 (0.75-1.92) 0.440
All-cause mortality Global CVD risk <20% 0.75 (0.52-1.08) 0.128 0.74 (0.48-1.15) 0.183
  Global CVD risk ≥20% 0.80 (0.62-1.01) 0.064 1.17 (0.54-2.57) 0.688
CVD Assigned to the intervention 1.58 (1.11-2.26) 0.011 1.43 (0.89-2.29) 0.143
  Not assigned to the intervention 1.01 (0.82-0.1.25) 0.896 1.33 (0.90-1.96) 0.148
All-cause mortality Assigned to the intervention 0.71 (0.49-1.02) 0.061 1.16 (0.62-2.15) 0.641
  Not assigned to the intervention 0.77 (0.61-0.98) 0.034 0.73 (0.44-1.20) 0.214
  1. * For one SD increment in each continuous predictor, obtained from multivariate Cox proportional hazards regression model adjusted for age, smoking, systolic blood pressure, family history of premature CVD, diabetes, antihypertensive drug usage, HDL and non-HDL cholesterol, FPG, and 2h-PCPG , plus the TLGS intervention measures.
  2. †calculated using "the Framingham general CVD prediction algorithm". (D'Agostino RB, Sr., Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB: General Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study. Circulation 2008, 117:743-753)
  3. CVD, cardiovascular disease; FPG, fasting plasma glucose; HDL-C, high density lipoprotein cholesterol; HR, hazard ratio; LAP, lipid accumulation product; Ln, naturally logarithmically transformed; 2h-PCPG, 2-hour post-challenge plasma glucose;